Literature DB >> 10197423

Interspecies pharmacokinetic comparisons and allometric scaling of napsagatran, a low molecular weight thrombin inhibitor.

T Lavé1, R Portmann, G Schenker, A Gianni, A Guenzi, M A Girometta, M Schmitt.   

Abstract

The objective of this work was to assess the pharmacokinetics of napsagatran, a low molecular weight thrombin inhibitor, after intravenous administration in a variety of laboratory animals, and prospectively to help design the first pharmacokinetic studies in man. Napsagatran is actively excreted into the bile and urine of various species and pronounced species-differences in its pharmacokinetics are observed. It is, therefore, an interesting compound to use in tests of the limitations of presently available inter-species scaling methods. The present data suggest that allometric exponent values which are consistent with the values expected for physiological processes and small organic molecules are not necessarily associated with successful predictions in man when active transport processes are involved in the disposition of the compounds. For example, compared with the values observed in man, the clearance (CL), non-renal clearance (CL(nr)) and the volume of distribution at steady state (Vd(ss)) were over-predicted by 3-, 7- and 2-fold, respectively, by use of allometry. Of the species tested, the cynomolgus monkey seemed to be the most useful for predicting kinetics in man when the approach based on concentration-time transformations was used. Thus, for half-life (t(1/2)), CL and Vd(ss), the observed mean values of 1.7 h, 459 mL min(-1) and 24 L kg(-1) in man were very close to the values predicted from the cynomolgus monkey (1.7 h, 652 mL min(-1) and 22 L kg(-1), respectively). The results show that there are large inter-species differences for kidney and liver excretion of napsagatran. This is probably because of the involvement of active transport processes, which compromised the kinetic extrapolation from animal to man, although a more thorough investigation of the transporters involved in the disposition of napsagatran is necessary to enable better understanding of the species differences observed.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10197423     DOI: 10.1211/0022357991772006

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  9 in total

1.  Allometric scaling of xenobiotic clearance: uncertainty versus universality.

Authors:  T M Hu; W L Hayton
Journal:  AAPS PharmSci       Date:  2001

2.  A semiphysiologically based pharmacokinetic modeling approach to predict the dose-exposure relationship of an antiparasitic prodrug/active metabolite pair.

Authors:  Grace Zhixia Yan; Claudia N Generaux; Miyoung Yoon; Rachel B Goldsmith; Richard R Tidwell; James E Hall; Carol A Olson; Harvey J Clewell; Kim L R Brouwer; Mary F Paine
Journal:  Drug Metab Dispos       Date:  2011-09-27       Impact factor: 3.922

3.  A novel strategy for physiologically based predictions of human pharmacokinetics.

Authors:  Hannah M Jones; Neil Parrott; Karin Jorga; Thierry Lavé
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

4.  Prediction of pharmacokinetic profile of valsartan in human based on in vitro uptake transport data.

Authors:  Agnès Poirier; Anne-Christine Cascais; Christoph Funk; Thierry Lavé
Journal:  J Pharmacokinet Pharmacodyn       Date:  2009-11-20       Impact factor: 2.745

5.  Hepatobiliary transport of YM466, a novel factor Xa inhibitor, in rats.

Authors:  Yuji Mano; Takashi Usui; Hidetaka Kamimura
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2006 Apr-Jun       Impact factor: 2.441

Review 6.  Methods to evaluate biliary excretion of drugs in humans: an updated review.

Authors:  Giulia Ghibellini; Elaine M Leslie; Kim L R Brouwer
Journal:  Mol Pharm       Date:  2006 May-Jun       Impact factor: 4.939

7.  Modelling and PBPK simulation in drug discovery.

Authors:  Hannah M Jones; Iain B Gardner; Kenny J Watson
Journal:  AAPS J       Date:  2009-03-12       Impact factor: 4.009

8.  Influence of structural variations in peptidomimetic 4-amidinophenylalanine-derived thrombin inhibitors on plasma clearance and biliary excretion in rats.

Authors:  Jörg Hauptmann; Torsten Steinmetzer; Helmut Vieweg; Peter Wikström; Jürg Stürzebecher
Journal:  Pharm Res       Date:  2002-07       Impact factor: 4.200

9.  The mastermind approach to CNS drug therapy: translational prediction of human brain distribution, target site kinetics, and therapeutic effects.

Authors:  Elizabeth Cm de Lange
Journal:  Fluids Barriers CNS       Date:  2013-02-22
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.